The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Recent reports have now implicated interleukin 12 and interleukin 23 ... The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

Ustekinumab is a human monoclonal antibody that targets the p40 protein, which is shared by interleukin (IL)-12 and IL-23 ...

Ustekinumab blocks proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23), which increase inflammation in your body. It has lower response rates, but it also has a lower rate of side ...

J&J’s pharma unit Janssen said Stelara is the first interleukin-12/23 inhibitor to be approved for UC, an inflammatory bowel disease which affects around 2.6 million people in Europe.

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...

Johnson & Johnson (J&J) has announced that Stelara (ustekinumab) has been approved by the European Commission (EC) to treat ...

About Otulfi Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses.

The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...

JERSEY CITY, N.J., March 13, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab), following approval by the U.S.